Our most recent article to be published in Epilepsia focuses on the anti-seizure and disease-modifying effects of cannabidiol in a range of animal seizure and epilepsy models. The recent FDA approval of Epidiolex for the management of Lennox-Gastaut and Draves’s Syndrome are the target patient population for this new therapeutic approach to the use of Read More…

Through the concerted efforts of the International League Against Epilepsy (ILAE) and the American Epilepsy Society (AES), a series of common data elements for preclinical epilepsy research have been developed. Dr. Melissa Barker-Haliski was co-chair of the Pharmacology Task Force to develop common data elements for preclinical antiseizure drug development. This work issued a number Read More…

Pharmacoresistant epilepsy affects roughly 30% of the over 65 million individuals worldwide with the disease. Unfortunately, these patients are still in need of improved treatment options. While we have over 20 antiseizure drugs on the market, the number of individuals with pharmacoresistant epilepsy has remained relatively unchanged. The Translational Epilepsy Research Laboratory has recently developed Read More…